Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000

<p>Abstract</p> <p>Background</p> <p>ML 3000 ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid) is an inhibitor of both cyclooxygenase and 5-lipoxygenase in vitro, and shows promise as a novel non-steroidal anti-inflammatory drug (N...

Full description

Bibliographic Details
Main Authors: Gupta Sandeep, Hammond Charles E, Goldenring James R, Smolka Adam J
Format: Article
Language:English
Published: BMC 2004-02-01
Series:BMC Gastroenterology
Online Access:http://www.biomedcentral.com/1471-230X/4/4
id doaj-70712b8741104af38cf1058754977356
record_format Article
spelling doaj-70712b8741104af38cf10587549773562020-11-25T03:07:17ZengBMCBMC Gastroenterology1471-230X2004-02-0141410.1186/1471-230X-4-4Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000Gupta SandeepHammond Charles EGoldenring James RSmolka Adam J<p>Abstract</p> <p>Background</p> <p>ML 3000 ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid) is an inhibitor of both cyclooxygenase and 5-lipoxygenase in vitro, and shows promise as a novel non-steroidal anti-inflammatory drug (NSAID). Unlike conventional NSAIDs which are associated with gastric ulcerogenic effects, ML 3000 causes little or no damage to the gastric mucosa, even though it significantly depresses gastric prostaglandin synthesis.</p> <p>Methods</p> <p>As part of an effort to clarify mechanisms underlying the gastric sparing properties of ML 3000, we studied the effects of ML 3000 on H,K-ATPase activity in vitro, on acid accumulation in isolated gastric parietal cells, and on IL-8 secretion by gastric epithelial cells in culture.</p> <p>Results</p> <p>SCH28080-sensitive H,K-ATPase activity in highly-purified pig gastric microsomes was dose-dependently inhibited by ML 3000 (IC<sub>50</sub> = 16.4 μM). Inhibition was reversible, and insensitive to ML 3000 acidification in the pH range 2.0–8.0. In rabbit gastric parietal cells,</p> <p>ML 3000 dose-dependently inhibited histamine-stimulated acid accumulation (IC<sub>50</sub> = 40 μM) and forskolin-stimulated acid accumulation (IC<sub>50</sub> = 45 μM). Lastly, in human gastric adenocarcinoma (AGS) cells, ML 3000 dose-dependently inhibited both baseline and IL-1β-stimulated (20 ng/ml) IL-8 secretion with IC<sub>50</sub>s of 0.46 μM and 1.1 μM respectively.</p> <p>Conclusion</p> <p>The data indicate that ML 3000 affects acid-secretory mechanisms downstream of cAMP mobilization induced by histamine H<sub>2</sub> receptor activation, that it directly inhibits H,K-ATPase specific activity, and that baseline gastric epithelial cell IL-8 secretory inhibition may be mediated by ML 3000 inhibition of 5-lipoxygenase activity. We conclude that these gastric function inhibitory data may underlie the gastric sparing properties of ML 3000.</p> http://www.biomedcentral.com/1471-230X/4/4
collection DOAJ
language English
format Article
sources DOAJ
author Gupta Sandeep
Hammond Charles E
Goldenring James R
Smolka Adam J
spellingShingle Gupta Sandeep
Hammond Charles E
Goldenring James R
Smolka Adam J
Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000
BMC Gastroenterology
author_facet Gupta Sandeep
Hammond Charles E
Goldenring James R
Smolka Adam J
author_sort Gupta Sandeep
title Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000
title_short Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000
title_full Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000
title_fullStr Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000
title_full_unstemmed Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000
title_sort inhibition of gastric h,k-atpase activity and gastric epithelial cell il-8 secretion by the pyrrolizine derivative ml 3000
publisher BMC
series BMC Gastroenterology
issn 1471-230X
publishDate 2004-02-01
description <p>Abstract</p> <p>Background</p> <p>ML 3000 ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid) is an inhibitor of both cyclooxygenase and 5-lipoxygenase in vitro, and shows promise as a novel non-steroidal anti-inflammatory drug (NSAID). Unlike conventional NSAIDs which are associated with gastric ulcerogenic effects, ML 3000 causes little or no damage to the gastric mucosa, even though it significantly depresses gastric prostaglandin synthesis.</p> <p>Methods</p> <p>As part of an effort to clarify mechanisms underlying the gastric sparing properties of ML 3000, we studied the effects of ML 3000 on H,K-ATPase activity in vitro, on acid accumulation in isolated gastric parietal cells, and on IL-8 secretion by gastric epithelial cells in culture.</p> <p>Results</p> <p>SCH28080-sensitive H,K-ATPase activity in highly-purified pig gastric microsomes was dose-dependently inhibited by ML 3000 (IC<sub>50</sub> = 16.4 μM). Inhibition was reversible, and insensitive to ML 3000 acidification in the pH range 2.0–8.0. In rabbit gastric parietal cells,</p> <p>ML 3000 dose-dependently inhibited histamine-stimulated acid accumulation (IC<sub>50</sub> = 40 μM) and forskolin-stimulated acid accumulation (IC<sub>50</sub> = 45 μM). Lastly, in human gastric adenocarcinoma (AGS) cells, ML 3000 dose-dependently inhibited both baseline and IL-1β-stimulated (20 ng/ml) IL-8 secretion with IC<sub>50</sub>s of 0.46 μM and 1.1 μM respectively.</p> <p>Conclusion</p> <p>The data indicate that ML 3000 affects acid-secretory mechanisms downstream of cAMP mobilization induced by histamine H<sub>2</sub> receptor activation, that it directly inhibits H,K-ATPase specific activity, and that baseline gastric epithelial cell IL-8 secretory inhibition may be mediated by ML 3000 inhibition of 5-lipoxygenase activity. We conclude that these gastric function inhibitory data may underlie the gastric sparing properties of ML 3000.</p>
url http://www.biomedcentral.com/1471-230X/4/4
work_keys_str_mv AT guptasandeep inhibitionofgastrichkatpaseactivityandgastricepithelialcellil8secretionbythepyrrolizinederivativeml3000
AT hammondcharlese inhibitionofgastrichkatpaseactivityandgastricepithelialcellil8secretionbythepyrrolizinederivativeml3000
AT goldenringjamesr inhibitionofgastrichkatpaseactivityandgastricepithelialcellil8secretionbythepyrrolizinederivativeml3000
AT smolkaadamj inhibitionofgastrichkatpaseactivityandgastricepithelialcellil8secretionbythepyrrolizinederivativeml3000
_version_ 1724671407251521536